The honest summary is that GLP-1 medications appear to reduce alcohol consumption in a specific studied population, at a specific dose, over a specific timeframe, and the mechanism has plausible biological support
Some people can wean to a lower maintenance dose, while others must take a higher dose to see continued positive results
LAD, Left anterior descending
The patient had a past medical history significant for May-Thurner Syndrome with iliac stent placement on anticoagulation, anxiety, and obesity (body mass index (BMI) of 34 kg/m 2 )
The Future of Manufacturing The scale of demand for GLP-1s has led some to question whether the current surge is sustainable or if the industry is at risk of overcorrecting in its efforts to meet it
However, the hyperglycemic effects of glucagon pose a challenge for its therapeutic application [77]